Eupraxia Pharmaceuticals (EPRX) to Release Quarterly Earnings on Monday

Eupraxia Pharmaceuticals (NASDAQ:EPRX) is projected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Eupraxia Pharmaceuticals to post earnings of ($0.14) per share for the quarter.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.01). On average, analysts expect Eupraxia Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Eupraxia Pharmaceuticals Trading Down 5.5 %

NASDAQ EPRX opened at $2.93 on Friday. Eupraxia Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $4.48. The company has a market capitalization of $104.41 million and a price-to-earnings ratio of -4.07. The stock’s 50 day moving average is $3.54 and its two-hundred day moving average is $3.16.

Analyst Upgrades and Downgrades

Separately, Craig Hallum initiated coverage on Eupraxia Pharmaceuticals in a research note on Friday, February 21st. They set a “buy” rating and a $12.00 price objective for the company.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.